Lifecare tests groundbreaking technology to analyze human data and strengthens
core team

29.11.2019, Oslo – Today Lifecare AS, a Norwegian life-science company,
announced that they are getting ready to test their sensing technology on human
data. This is a significant advancement in the development of the solutions to
address the diabetes epidemic.
 
Lifecare AS researches and develops miniature sensors for convenient glucose
monitoring for a global market. The testing is the next phase of the development
of the technology and it enables the company to generate human data, earlier
than expected, with the groundbreaking technology. 

“This is another step towards miniaturizing the Sencell Glucose Sensor,” says Dr
Andreas Pfûtzner, CSO, Lifecare. “The sensor has now been developed to a point
where it is already smaller than the initial targeted size. This allows the
sensing element to be put into a hypodermic needle. A needle sensor will also
represent an additional product opportunity. We are proud that we are now able
to start the testing after initiating the regulatory process for the first
clinical study.” 

Lifecare is developing an implantable continuous glucose sensor based on its
proprietary osmotic pressure cell technology. The news about the upcoming tests
comes after Lifecare announced in April 2019 that its nanosensor technology has
been shown in laboratory experiments to accurately measure pressure changes
derived from substantially smaller osmotic pressure chambers than previously
available. 

Strengthening core team

In this process, Lifecare has increased its team with two talented new
colleagues; Dr. Konstantin Kloppstech, a world leading expert in
sensor-technology and former Head of Technology at cantiMED, and Dr. Frank
Flacke, the former Medical Director Devices in the global CVD division of
Sanofi. Both have now joined Lifecare’s core team and are together spearheading
the sensor development. Kloppstech and Flacke have purchased shares in Lifecare
from the Chairman of the Board, Christian Saure – please see separate press
release.